2023 annual financial data
Galectin Therapeutics 2023 Operating margin
Direct answer
Operating margin was Not calculable.
Operating income was -38,072,000 USD and net income was -41,066,000 USD.
Operating cash flow was -32,965,000 USD.
Get free Galectin Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 USD
- Operating income
- -38,072,000 USD
- Net income
- -41,066,000 USD
- Operating cash flow
- -32,965,000 USD